WASOG 2026
Steroid-Sparing and Pulmonary Stability Across XTMAB-16 Dose Regimens in Pulmonary Sarcoidosis: Cohort-Level Findings from XTMAB-16-201 Part A
Xentria presents additional data around its lead investigational therapy, XTMAB-16, at the WASOG Congress 2026. Xentria provided cohort-level analyses that supported selection of the XTMAB-16 4 mg/kg Q4W dose for continued development.
Key points from the poster include:
- During corticosteroid withdrawal, XTMAB-16-treated participants more consistently maintained FVC stability, whereas placebo-treated participants showed FVC declines during tapering.
- Among evaluated dose regimens, XTMAB-16 4 mg/kg Q4W demonstrated the most balanced descriptive profile across corticosteroid reduction, pulmonary stability, exposure, and immunogenicity trends.
About XTMAB-16
XTMAB-16 is novel biologic developed by Xentria to address the unmet medical need for patients with sarcoidosis, a rare inflammatory disease that affects multiple organs in the body. XTMAB-16 is a monoclonal antibody designed to suppress the inflammatory pathways promotion of sarcoidosis granuloma formation. No TNF-α inhibitor is currently approved for the treatment of sarcoidosis. Extensive analyses have been conducted to demonstrate the physio-chemical properties and pharmacology of XTMAB-16 as a TNFα inhibitor. The clinical study of this effect remains ongoing.
XTMAB-16 is an investigational product candidate and is not approved or commercially available in the United States. Any future availability is subject to successful clinical development and regulatory approval.
About Sarcoidosis
Sarcoidosis is a chronic, multisystem inflammatory disorder of unknown etiology that is characterized by the presence of noncaseating epithelioid granulomas, accompanied by infiltration of mononuclear cells and destruction of microarchitecture. The disease can affect the skin, eyes, heart, and central nervous system, and >90% of cases involve the lungs. While medications for systemic organ involvement often control this disease, some patients fail to respond to initial treatments and require additional targeted therapy, resulting in significant costs and treatment burdens. This disease presents a significant unmet medical need and a very important area of research and development for Xentria.
World Association for Sarcoidosis and Other
Granulomatous Disorders (WASOG) Congress 2026
Date: July 15-17, 2026
Location: Porto, Portugal
Presentation: Abstract poster